Rigorous research and developments on other BMP applications have become critical differentiating strategy. However, Rising Traumatic Injury Caseloads Remain Pivotal to Growth.

In its latest market analysis, ResearchMoz has revealed that the global market revenue of bone morphogenetic proteins will clock nearly US$ 704 Mn by 2027. ResearchMoz uncovers the global bone morphogenetic proteins market in detail in its report that includes the drivers, restraints, opportunities, threats and competitive topography during the forecast period.

Players Uncovering Potential Avenues in Dentistry

The utilization of bone morphogenetic proteins is not only concentrated on osteogenic regeneration. Instead, BMP producers, along with medical researchers, are conducting extensive studies in other areas, including periodontal regeneration and tooth conservation procedures. In dentistry, BMP-2 is seeing huge demand uptick in several medical procedures, including sinus lift augmentation, alveolar bone regeneration, and dental implants. Such discoveries are influencing market players to devise innovative biomaterials for BMP delivery in these potential avenues.

BMPs to Act as Possible Bridge between Bone Metabolism with Obesity

Riding the wave of meticulous Research and Development, players in bone morphogenetic proteins market are striving to determine relationship between bone metabolism and obesity as well as glucose metabolism. Studies have highlighted impact of bone morphogenetic proteins – BMP9, BMP7, BMP6, BMP4, and BMP2 – on pathophysiological process of glucose metabolism and obesity beyond bone metabolism. Furthermore, holistic understanding of impacts of bone morphogenetic proteins could help market players better understand bone metabolism in obesity and type-2 diabetes.

Analysts’ Views

The market is witnessing major impetus from increasing spinal injury caseloads, especially in Gen X and geriatric cohorts, and conducive regulatory environment. Moreover, bone morphogenetic proteins easily align with the intensifying awareness and need for minimally-invasive treatments. In order to sustain their revenue growth, players are joining hands with healthcare researchers to tap into potential applications of bone morphogenetic proteins.

“During 2020-2021, about 470, 000 people suffered work-related musculoskeletal disorders. Of those caseloads, around 40% patients endured spinal injuries. Bone morphogenetic proteins promote formation and repairment of affected bones and cartilages. This reduces dependence on spinal screws and rods and, thus, the painful procedure of invasive surgeries,” elucidates ResearchMoz

APAC BMP Market to Grow at Breakneck Speed

The report underscores fast-paced growth of bone morphogenetic proteins market in Asia Pacific (APAC). Increasing healthcare spending, especially in

China, India, and Singapore, and rising prominence of recombinant human bone morphogenetic proteins (rhBMP) are critical growth engines.

Besides, cost-effective healthcare services, superior hospitality, and leading-edge medical technologies (MedTech) have bolstered medical tourism in APAC. Thailand, Malaysia, and India are leading the pack in this theme.

Competitive Landscape

ResearchMOZ underscores the competitive gradient of the bone morphogenetic proteins market which would enable the new entrants to extract factual information regarding the strategies adopting by the leading players in order to dive deeper into the uncharted regions and grab their positions.

The leading players of the bone morphogenetic proteins market are

• ProSpec
• DePuy Synthes
• Ember Therapeutics Inc
• Sigma-Aldrich Corporation
• R&D Systems
• Cellumed Co. Ltd

Key Takeaways

ResearchMoz establishes a research-based projections and information that unveils the larger picture of the global bone morphogenetic proteins market to help stakeholders to take informed decisions in order to succeed in this arena. Some of the key takeaways from the reports include-

• The bone morphogenetic proteins to grow at a 2.9% CAGR between 2021 to 2027, exhibiting estimated value of nearly USD 704 million.
• The sports related injuries to remain the dominant factor driving the market because of growing adoption of minimally invasive surgeries.
• Osteoarthritis in geriatric population to spur the demand for bone morphogenetic proteins market.
• Spinal fusion to remain the target application.
• North America will maintain its supremacy over the market owing to advanced healthcare system and increasing geriatric population with degenerative bone diseases.

Type Outlook (Revenue, USD Million)

• rhBMP 2
• rhBMP 7

Application Outlook (Revenue, USD Million)

• Spinal fusion
• Trauma
• Reconstructive
• Oral maxillofacial surgery
• Others

Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France

Asia Pacific

• China
• India
• Japan
• South Korea